NuVasive Climbs Back to Pre-Pandemic Levels in 2Q

NuVasive logo

NuVasive reported 2Q21 orthopedic revenue of USD $294.8 million, +44.8% vs. 2Q20. Compared to the second quarter of 2019, the company grew +0.9% with moderate U.S. sales declines offset by improved international performance. For the full year 2021, NuVasive expects revenue between $1.19 billion and $1.21 billion. At the mid-point, that...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us